Nektar in pact to acquire Aerogen

Nektar Therapeutics, a San Carlos, California-based drug delivery developer, said Monday it plans to acquire Aerogen in a deal worth about $32 million, including $8 million in cash and $24 million in stock.The deal is expected to close during the fourth quarter.

- read this story from MarketWatch for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.